Bringing the Oncology Community Together

Genmab Focuses Oncology Research on Monoclonal Antibodies

Tony Berberabe, MPH
Published Online: Thursday, February 6, 2014
GenmabGenmab, the publicly traded, international biotechnology company, has an oncology pipeline that focuses on two classes of drugs: naked antibodies and antibody drug conjugates (ADCs). Its products are being developed in more than 70 active clinical studies, and its lead agent, ofatumumab (Arzerra), was launched after only 8 years in development. Other products undergoing clinical investigation at Genmab include the antibody daratumumab and the ADC HuMax- TF-ADC.

Results from a recent phase III study presented at the 55th American Society of Hematology Annual Meeting in New Orleans, Louisiana, demonstrated improved clinical outcomes when ofatumumab was added to chlorambucil in patients with previously untreated chronic lymphocytic leukemia (CLL). The data showed that median progressionfree survival, overall response rate, complete response rate, and the treatment-free period were all superior with the addition of ofatumumab to chlorambucil compared with chlorambucil alone

Ofatumumab is a monoclonal antibody that targets an antibody determinant (epitope) that’s found on the B-lymphocyte antigen CD20. Ofatumumab attaches to the CD20 molecule, which is found on the surface of B cells. B cells become cancerous in CLL. The CD20 molecule is found on over 90% of B-cell lymphomas, as well as other lymphoid tumors of B-cell origin.

Genmab and GlaxoSmithKline comarket ofatumumab. It is approved for patients with CLL who are refractory to fludarabine and alemtuzumab. The FDA recently granted priority review to a supplemental Biologics License Application for ofatumumab in combination with an alkylator-based therapy in treatment-naïve CLL patients who are not eligible for fludarabine-based therapy. A decision on the indication will be made on or before April 19.

The most common adverse reactions reported with ofatumumab are neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections. The most common serious adverse reactions seen are infections (including pneumonia and sepsis), neutropenia, and pyrexia.

Ofatumumab is undergoing investigation in other oncology and autoimmune diseases including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), Waldenström’s Macroglobulinemia, pemphigus vulgaris, and relapsing-remitting multiple sclerosis.

Another monoclonal antibody in Genmab’s pipeline is daratumumab, a human CD38 antibody that is undergoing investigation in multiple myeloma. The drug could also have potential in other hematological malignancies in which CD38 is expressed, including DLBCL, CLL, acute lymphoblastic leukemia, acute myeloid leukemia, follicular lymphoma, and mantle cell lymphoma.

The FDA has granted daratumumab Fast Track designation as a potential treatment in patients with multiple myeloma. It is indicated in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and IMiD.

HuMax-TF-ADC is an ADC that targets tissue factor, a protein involved in tumor signaling and angiogenesis. The conjugate is highly expressed in solid tumors, with rapid internalization. These characteristics make it a viable target for an ADC approach. It is being developed in collaboration with Seattle Genetics. HuMax-TF-ADC is undergoing a phase I dose escalation trial to treat multiple solid tumors.

Genmab’s Oncology Pipeline

Genmab’s Oncology Pipeline

Related Articles
Novartis Plans Acquisition of GSK’s Oncology Products
GSK and Novartis have struck a deal that will move all of GSK's oncology assets to Novartis, all of Novartis' non-flu-related vaccines to GSK, and will result in a joint consumer healthcare venture.
Greater Use of Nonphysician Providers Seen in Office Settings
Employing nonphysician providers (NPPs) by physician practices has grown in the past 15 years
Teaching Billing and Coding Techniques Benefit Second-Year Students
In addition to the clinical skills lectures included in medical school curriculum, second-year medical students at Rutgers New Jersey Medical School in Newark, NJ, are also receiving a course in understanding the basics of billing and coding
Role of Radiation Therapy in Hodgkin Lymphoma
Panelists discuss the evolving role of radiation therapy in Hodgkin lymphoma and whether new approaches lessen the long-term toxicity traditionally associated with this treatment modality.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.